Genetic variants associated with uric acid levels mainly include purine metabolism (e.g., XDH, HPRT1), urate transporters (e.g., SLC2A9, SLC22A12), and renal urate processing regulators (e.g., ABCG2)
Developed in the late 1990s by researchers at Merck & Co., its original purpose was to combat conditions like muscle wasting [1]
Researchers posited that the peptide caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images . Conversely, Ipamorelin might preferentially target a distinct class of receptors believed to be growth hormone secretagogue receptor 1a (GHS-R1a), commonly called ghrelin receptors, which endogenously respond to the hormone ghrelin, according to research by Jimnez-Reina et al
A 150-pound person and a 250-pound person receiving the same dose have different effective concentrations
Ipamorelin vs older GHRPs Selectivity matters in clinical conversations